All News
ACR21 Best Abstracts - Day 2
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
Read Article
Day 1 Report from ACR21
The first full day of Abstracts and Presentations from ACR Convergence, was full of highly engaging sessions, quality posters and unique presentations. To hear more about the best of the best, I would encourage you to look at our Day 1 Recap Video and Day 1 ACR Best Abstracts. Here are a few of my favorites from the first day.
Read Article
AQUILA study, SEC improved disease activity, depression of PsA patients in both men and women. Women showed overall higher burden of disease. SEC effective up to 52 weeks with high treatment retention rates irrespective of gender @RheumNow #ACR21 Abst#1334 https://t.co/9cPGq5M648 https://t.co/iTrkRWoot0
Dr. Antoni Chan synovialjoints ( View Tweet)
SEC demonstrated significantly longer time to flare vs PBO w/ sustained improvement of ERA and JPsA signs and symptoms up to Wk 104. No new safety signals. Plenary Abs 1424 #ACR21 #RheumNow @RheumNow https://t.co/VF2HmJ3Ha9 https://t.co/ApYFusADHX
Dr. Rachel Tate uptoTate ( View Tweet)
Post-hoc analysis of Deucravacitinib (TYK2i) for tx of PsA showed similar efficacy in pts with and without background csDMARD use.
⭐️>60% w/ background csDMARD use, majority of which was MTX
⭐️no difference in AE
#ACR21
Abs#1352
@RheumNow
https://t.co/nIJT7rNkJP https://t.co/bq0x1Ywguo
Robert B Chao, MD doctorRBC ( View Tweet)
Younger age, male gender, geographic region, lower weight and BMI, dactylitis+ or enthesitis+, lower scores Pt-Pain, PtGA, TJC and HAQ-DI were baseline predictors for achieving MDA and DAPSA LDA at Week 56 in UPA treated patients @RheumNow #ACR21 Abst#1348 https://t.co/FSXarBoBM1 https://t.co/UMCjr6eCRm
Dr. Antoni Chan synovialjoints ( View Tweet)
Physical exercise did not increase BME disease in SIJ and spine in PsA. The risk of increased BME after 11 weeks of HIIT was not higher compared to controls in a cohort of PsA patients with low to moderate disease activity @RheumNow #ACR21 Abst#1362 https://t.co/DHj4D5Ojb1 https://t.co/J4KV5zdpey
Dr. Antoni Chan synovialjoints ( View Tweet)
Abst1424 #ACR2021 @RheumNow study of SEC in children w/ERA or JPsA : 72% reduced flare risk. Improved JADAS-27 score in both the ERA and JPsA categories. ⬇️ disease activity, enthesitis count & joints with active arthritis. adverse events & serious AEs in the SEC & PBO comparable https://t.co/J4MdxeYxWZ
Olga Petryna DrPetryna ( View Tweet)
PsO pts not on biologics had a ⬆️ risk of PsA compared to those on biologics
⭐️HR 1.39
⭐️retrospective cohort study w/ >1300 cases
Abs#1355
#ACR21
#ACRBest
@RheumNow
https://t.co/tL37we3lwc https://t.co/SAexvn9HMb
Robert B Chao, MD doctorRBC ( View Tweet)
In PsA patients with low baseline CRP treated with IXE or ADA, a favorable reduction in pain was observed for IXE-treated
patients, irrespective of controlled or non-controlled inflammation, as
measured by CRP or SJC improvement @RheumNow #ACR21 Abst#1341 https://t.co/Nl78oASmf5 https://t.co/2qSXQr2sQS
Dr. Antoni Chan synovialjoints ( View Tweet)
Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect. Anaemia resolution associated good outcomes, but many with good outcomes still anaemic. Abstr#1331 #ACR21 @RheumNow https://t.co/LL63Qc0nk5
Richard Conway RichardPAConway ( View Tweet)
Study on enthesitis response to biologic Rx
⭐️TNFI caused a 2❎ 🔽mean ActiveMASEI score compared to secukinumab
⭐️ 🔽PASI and DLQI score more in TNFI than Secukinumab
🔰Superiority of TNFi versus secukinumab in regards to active enthesitis
Abst#1356 #ACR21 @Rheumnow https://t.co/wdzMYmn8AJ
swethaann23 swethaann23 ( View Tweet)
Dr Elliott presenting on US assessment of enthesitis with TNFi vs secukinumab. Surprisingly TNFi showed a more marked decrease in US enthesitis. Abstr#1356 #ACR21 @RheumNow https://t.co/XXgYMgkMyP
Richard Conway RichardPAConway ( View Tweet)
Guselkumab (IL23p19 inhibitor) positive effect on axial outcomes in PsA, durable response across 2 years. Abstr#1330 #ACR21 @RheumNow https://t.co/8LOSdzCvRc
Richard Conway RichardPAConway ( View Tweet)
A meta-analysis of 5 cohort studies showed that PsA is significantly associated with vertebral fractures pooled OR 2.09 (95% CI, 1.11 – 3.96; I2 70%). The review was not suggestive of publication bias
@RheumNow #ACR21 Abst#1304 https://t.co/rjC776FXUA https://t.co/QvMWxN6ZZ7
Dr. Antoni Chan synovialjoints ( View Tweet)
Meta-analysis shows increased risk of vertebral fracture in PsA, OR 2.09. Abstr#1304 #ACR21 @RheumNow https://t.co/kTrR7I3HA0
Richard Conway RichardPAConway ( View Tweet)
Minimal disease activity achievement in PsA achieved by 22.8% in 6 mo of b/ts DMARD
MDA achievers were:
➡️Younger
➡️🔽 Disease duration;
➡️ Male
➡️Non-obese
➡️bDMARD-naïve at baseline
➡️🔼 probability achieving MDA components➕MCID PROMs at 6 mo
Abst# 1344 #ACR21 @Rheumnow
swethaann23 swethaann23 ( View Tweet)
Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More pronounced in TNFi than IL-17 or JAKi. Abstr#1327 #ACR21 @RheumNow https://t.co/qhgVlW72uM
Richard Conway RichardPAConway ( View Tweet)
AS and PsA: Mortality vs Gen Pop (meta-analysis)
AS:
👉⬆️All-cause
👉⬆️CVD
PsA:
👉All-cause not higher
👉⬆️CVD, Respiratory, and Infectious etiologies
Important to consider CVD and other comorbidities.
https://t.co/9K4qNpYvMb
#ACR21 Abst#0569 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
"Healthier moms lead to healthier babies. This is how I frame the discussion regarding medications and PsA in my practice (with regard to reproductive health)." Dr. Talabi #ACR21 @RheumNow #RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
